Fibrosis Clinical Trials 2024

Fibrosis Clinical Trials 2024

Fibrosis research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in fibrosis clinical trials today.

Fibrosis Clinical Trials

Here are the 6 most popular medical studies for fibrosis

Popular filter options for fibrosis trials

Myelofibrosis Clinical Trials

View 27 Myelofibrosis medical studies.

Palo Alto, California

Tyrosine Kinase Inhibitor

CEP-701 (Lestaurtinib) for Polycythemia Vera

Recruiting1 awardPhase 1 & 2
Palo Alto, California

Myelofibrosis is the gradual replacement of bone marrow (place where most new blood cells are produced) by fibrous tissue which reduces the body's ability to produce new blood cells and results in the development of chronic anemia (low red blood cell count). One of the main distinctions of myelofibrosis is "extramedullary hematopoesis", the migration or traveling of the blood-forming cells out of the bones to other parts of the body, such as the liver or spleen, resulting in an enlarged spleen and liver. Treatment for myelofibrosis is unsatisfactory and there is no medication that is specifically used in the treatment of myelofibrosis. There is a protein that is found to be present in the majority of myelofibrosis patients (JAK2) and the drug Lestaurtinib is being studied to see if it will stop this protein from functioning and thereby help control the disease. This study is divided into two Phases (1 & 2). In phase 1 we will be looking for the dose of study medication (Lestaurtinib) that will be the highest dose a patient can take without experiencing serious side effects, maximum tolerated dose (MTD). In phase 2, after the MTD dose has been established in phase 1, we will be investigating how well CEP-701 (Lestaurtinib) works at suppressing the protein (JAK2). The investigators also wish to find out important biologic characteristics or features of myelofibrosis through an additional correlative biomarker study (MPD-RC #107). The correlative biomarker study is a study that is related to the main study, but is looking to answer different questions than the main study. The purpose of the biomarker study is to understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases, while the main study is trying to find out how well CEP-701 (Lestaurtinib) will work in treating the myeloproliferative disease.

Cystic Fibrosis Clinical Trials

View 23 Cystic Fibrosis medical studies.

Phase 3 Fibrosis Clinical Trials

View 96 phase 3 fibrosis medical studies.

Fibrosis Clinical Trials With No Placebo

View 96 fibrosis medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to fibrosis

What are the top hospitals conducting fibrosis research?

When it comes to pushing the boundaries in the field of fibrosis research, some leading hospitals are making significant strides. In Boston, renowned for its medical excellence, Boston Children's Hospital is at the forefront with nine active clinical trials focused on fibrosis. With a remarkable 58 completed trials dedicated to this condition since their first recorded trial in 2004, they have established themselves as a powerhouse in advancing our understanding and treatment of fibrosis. The University of Alabama at Birmingham is another prominent institution driving progress with eight ongoing fibrosis trials and an impressive tally of 75 previous studies since their inaugural trial in 2004.

In Kansas City, the University of Kansas Medical Center is actively contributing to combating fibrosis through seven ongoing clinical trials. They have built upon their solid foundation by conducting 52 previous trials since recording their first investigation into fibrosis in 2005. Similarly dedicated to unraveling the mysteries surrounding this condition, Nationwide Children's Hospital in Columbus has seven active clinical trials targeting fibrosis alongside a commendable history of completing 64 previous investigations dating back to their initial work on this topic also starting from around2005.

Lastly but certainly not least important is The Children's Mercy Hospital situated within Kansas City who have made substantial contributions through six ongoing clinical tests specifically designed for tackling various aspects related to Fibrois; having embarked on such journeys only about twelve years ago (in just while before2010). Although considered smaller-scale compared to other institutions mentioned above yet they hold utmost value due dedication demonstrated throughout development eighteen all-time projects till now.

These top-ranking hospitals collectively represent beacons hope for those grappling with Fibrosic conditions; showcasing how collective efforts drive real change towards disease understanding which leads us path-breaking solutions betterment countless lives worldwide

Which are the best cities for fibrosis clinical trials?

Houston, Texas, New york, New York, and Boston, Massachusetts emerge as the leading cities for fibrosis clinical trials. Houston leads the pack with 29 ongoing studies focused on treatments like Inhaled Treprostinil and belapectin. Following closely behind is New York with 28 active trials exploring interventions such as belapectin and Fazirsiran. Boston also plays a significant role in fibrosis research with 27 ongoing trials investigating VX-121/TEZ/D-IVA and ELX/TEZ/IVA. These cities offer individuals with fibrosis access to cutting-edge clinical trials that hold promise for improved treatment outcomes.

Which are the top treatments for fibrosis being explored in clinical trials?

Exciting advancements in fibrosis treatment are being explored through various clinical trials. Leading the way is Saroglitazar Magnesium 2 mg, currently involved in two active trials and holding its ground with two all-time fibrosis trials since it was first listed in 2021. Another promising contender is Losartan, showing potential with two ongoing trials and a total of nine all-time fibrosis studies dating back to 2007. ELX/TEZ/IVA is also making strides, participating in two active trials along with an impressive record of 19 all-time fibrosis trials since its introduction in 2018. Finally, we have Inhaled Treprostinil joining the ranks, engaging in two current research projects after entering the scene just this year alongside four previous fibrosis studies. The dedication shown by these treatments demonstrates their commitment to combating this challenging condition and offering hope to those affected by it

What are the most recent clinical trials for fibrosis?

Exciting advancements are being made in the field of fibrosis treatment, with several recent clinical trials showcasing promising potential. Among them is BMS-986278 Dose 1, which has entered Phase 3 and holds great promise for patients grappling with this condition. Additionally, captopril has shown encouraging results in both Phase 1 and Phase 2 trials, offering hope for improved outcomes in fibrosis management. The efficacy of efzofitimod at a dosage of 450 mg is also under investigation in a Phase 2 study, providing further avenues for exploration. Lastly, rifaximin oral tablets have demonstrated potential benefits as well through their advancement into Phases 2 and 3 trials. These ongoing research endeavors serve as beacons of optimism for individuals affected by fibrosis and offer new possibilities to enhance their quality of life.

What fibrosis clinical trials were recently completed?

A range of clinical trials focusing on fibrosis have recently been completed, showcasing the dedication of researchers in advancing treatments for this condition. Notably, Vertex Pharmaceuticals Incorporated sponsored several trials: ELX/TEZ/IVA concluded in May 2022 and was also completed in January 2022 and November 2020. Nabriva Therapeutics AG's trial investigating Lefamulin finished in March 2022, while Insmed Incorporated's Brensocatib trial wrapped up in November 2021. Stanford University conducted a trial involving Empagliflozin 10 MG that ended in November 2021 alongside University of Michigan's investigation into Lactulose. AbbVie-sponsored CREON concluded its trial in October 2021. Additional studies include those by Armata Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, NGM Biopharmaceuticals, Inc., Pliant Therapeutics, Inc., Vertex Pharmaceuticals Incorporated (LUM/IVA), and St. Louis University (SmartPill Motility System & PillCam Patency Capsule). These recent breakthroughs offer hope for patients affected by fibrosis.